WT1235, a ninemer peptide derived from Wilms' tumor gene product, is a candidate peptide for the vaccination of HLA-A*0201-positive patients with hematopoietic malignancies [2]

International Journal of Hematology

Volumn 82, Issue 5, 2005, Pages 458-459

  Li, Zheyu ^a   Oka, Yoshihiro ^a   Tsuboi, Akihiro ^a   Masuda, Tomoki ^a   Tatsumi, Naoko ^a   Kawakami, Manabu ^a   Fujioka, Tatsuya ^a   Sakaguchi, Nao ^a   Nakajima, Hiroko ^a   Fujiki, Fumihiro ^a   Udaka, Keiko ^b   Oji, Yusuke ^a   Kawase, Ichiro ^a   Sugiyama, Haruo ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; EPITOPE; GENE PRODUCT; HLA A ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; WT1 235 VACCINE; WT1 PROTEIN; HLA A*0201 ANTIGEN; HLA-A*0201 ANTIGEN; OLIGOPEPTIDE;

CANCER IMMUNOTHERAPY; CANCER REGRESSION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG MECHANISM; GENE EXPRESSION; HEMATOLOGIC MALIGNANCY; HUMAN; IN VIVO STUDY; LETTER; LEUKEMIA CELL LINE; PERIPHERAL BLOOD MONONUCLEAR CELL; VACCINATION; ANTIGEN PRESENTATION; BLOOD DISEASE; CELL STRAIN K 562; IMMUNOLOGY; METHODOLOGY;

ANTIGEN PRESENTATION; CANCER VACCINES; EPITOPES, T-LYMPHOCYTE; HEMATOLOGIC NEOPLASMS; HLA-A ANTIGENS; HUMANS; K562 CELLS; OLIGOPEPTIDES; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION; WT1 PROTEINS;

EID: 33646440762     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.05107     Document Type: Letter

References (13)

1. Inoue K, Sugiyama H, Ogawa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood. 1994;84:3071-3079.
2. Inoue K, Ogawa H, Sonoda Y, et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood. 1997;89: 1405-1412.
3. Yamagami T, Sugiyama H, Inoue K, et al. Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. Blood. 1996;87:2878-2884.
4. Tsuboi A, Oka Y, Ogawa H, et al. Constitutive expression of the Wilms' tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor (G-CSF). Leak Res. 1999;23:499-505.
5. Oka Y, Elisseeva OA,Tsuboi A, et al. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product. Immunogenetics. 2000;51:99-107.
6. Oka Y, Udaka K, Tsuboi A, et al. Cancer immunotherapy targeting Wilms' tumor gene WT1 product. J Immunol. 2000;164: 1873-1880.
7. Ohminami H, Yasukawa M, Fujita S. HLA class i-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood. 2000;95:286-293.
8. Tsuboi A, Oka Y, Udaka K, et al. Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues. Cancer Immunol Immunother. 2002;51:614-620.
9. Oka Y, Tsuboi A, Taguchi T, et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA. 2004; 101:13885-13890.
10. Mailander V, Scheibenbogen C, Thiel E, Letsch A, Blau IW, Keilholz U. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia. 2004;18:165-166.
11. Gao L, Bellantuono I, Elsasser A, et al. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood. 2000;95:2198-2203.
12. Bellantuono I, Gao L, Parry S, et al. Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL. Blood. 2002;100:3835-3837.
13. Oka Y, Tsuboi A, Murakami M, et al. Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. Int J Hematol. 2003;78:56-61.